ContractClinical Trial Agreement • July 15th, 2024
Contract Type FiledJuly 15th, 2024CLINICAL TRIAL AGREEMENT This CLINICAL TRIAL AGREEMENT (this“Agreement”) is valid as of the date of signature by the last Party and effective as of the date of publication in the Contract Registry or the date of authorization of the Clinical Trial, whichever is later, by and between: Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb, having an office at Route 206 and Province Line Road, Princeton, NJ 08543, USA Tax Identification No: 22-2711928 (“SPONSOR”), and FAKULTNÍ NEMOCNICE KRÁLOVSKÉVINOHRADY, represented by MUDr. Jan Votava, MBA, Director, having address at Šrobárova 1150/50, Praha 10, 100 34, Czech RepublicIdentification No: 00064173Tax Identification No: CZ00064173 Reference No.: 22/2024Cost center: 52222 (“INSTITUTION”), and MUDr. Heidi Móciková, Ph.D., (“INVESTIGATOR”). individually or collectively, as the case may be, referred hereto as the “Party” or “Parties”. PRELIMINARY STATEMENTS A. SPONSOR requests INSTITUTION and INVESTIGATOR to conduct a clinica